Less Ads, More Data, More Tools Register for FREE

Pin to quick picksDuke Capital Regulatory News (DUKE)

Share Price Information for Duke Capital (DUKE)

Share Price is delayed by 15 minutes
Get Live Data
26.00    0.00 (0.00%)
Bid:
25.50
Ask:
26.50
Spread: 1.00 (3.922%)
Market Cap: £130.91m
DUKE Live PriceLast checked at - London Stock Exchange

Intraday Duke Capital Share Chart

Modification of Partners' Agreements - Amendment

14 May 2019 13:00

RNS Number : 9960Y
Duke Royalty Limited
14 May 2019
Β 

Β 

Β 

The following amendments have been made to RNS number 8869Y, entitled 'Modification of Terms with Recently Acquired Royalty Partners', which was released at 7.00 a.m. on 14 May 2019.

Β 

The date for the deferred consideration to be paid to Capital Step, subject to the achievement of 'performance related milestones', is 31 March 2020. All other details remain the same. The full amended text is shown below.

Β 

14 May 2019

Β 

Duke Royalty Limited

("Duke Royalty", "Duke" or the "Company")

Modification of Terms with Recently Acquired Royalty Partners

Β 

Duke Royalty Limited (AIM: DUKE), a provider of alternative capital solutions to a diversified range of profitable and long-established businesses in Europe and abroad, is pleased to announce modifications to the terms of the following agreements which will increase near term revenues for the Company.

Β 

The Company has reached agreements with royalty partners Welltel (Ireland) Limited ("Welltel"), a telecommunications services company, media company Pearl & Dean Cinemas Limited ("the Pearl & Dean Group"), and Xtremepush Limited ("Xtremepush"), a technology solutions company, all of which were acquired via the recent Capital Step acquisition, to modify the terms of existing agreements. This is expected to increase gross revenues to Duke by at least Β£3.7 million in aggregate over the next five years.

Β 

Capital Step was acquired by Duke Royalty in February 2019, prior to which it offered a 'unitranche' solution, which is a perpetual royalty paired with a senior secured loan, which amortises over a three to five year term. Pursuant to the existing arrangements with these three royalty partners, a total of Β£5.5 million of capital deployed amongst them was due to begin repayments in various instalments starting from December 2018, with the entire Β£5.5 million of capital expected to be repaid by 31 March 2022.

Β 

Modifications of terms have now been agreed; for Welltel and Xtremepush, the maturity dates of the senior loan facilities have been extended until 30 April 2024, when the full repayment of principal will be due. For the Pearl and Dean Group, the original agreement saw half of the royalty amortising over three years, and the other half as a perpetual term. The parties have agreed to make the entire amount a perpetual royalty, with the return calculated as a fixed percentage of gross revenues, subject to a floor and a cap. All other terms of the agreements remain the same.

Β 

As a result of removing the capital repayments, Duke has increased the gross revenues that it expects to receive, assuming the agreements are in place until 30 April 2024, by at least Β£3.7 million. By extending the royalty agreement in perpetuity, the actual revenue could exceed this figure depending on future revenue growth of the Pearl & Dean Group, as Β£3.7 million only includes the minimum contractual royalties (ie. the 'floor') due in the next five years.Β 

Β 

These modifications represent an increase of more than 25% to the Capital Step portfolio's expected revenues per year for the next five years and need no additional overhead costs. Importantly, these contract modifications are excluded from the 'performance related milestones for the period ended 31 March 2020' which the Capital Step portfolio needs to deliver in order to receive a deferred payment from Duke Royalty, as announced by the Company on 4th February.

Β 

Neil Johnson, CEO of Duke Royalty, said:

"We are pleased to agree these modifications, which means that our royalty partners can increase short term cash flow and Duke can maximise near term revenues. We recognised the strength and credit quality of the acquired royalty partners and the Board identified this as a way of unlocking value of the Capital Step royalty agreements for Duke Royalty shareholders. We are also looking at the opportunity to deploy further capital at accretive returns via follow-on investments into the acquired royalty partners and look forward to updating the market in due course."

Β 

**ENDS**

Β 

For further information, please contact www.dukeroyalty.com, or contact:

Β 

Duke Royalty Limited

Neil Johnson / Charlie Cannon-Brookes

Β 

+44 (0) 1481 741 240

Cenkos Securities plcΒ 

(Nominated Adviser and Broker)

Β 

Julian Morse / Michael Johnson / Stephen Keys / Callum Davidson

+44 (0) 207 397 8900

Newgate Communications

(PR)

Β 

Elisabeth Cowell / Ian Silvera / Tom Carnegie

+44 (0) 20 3757 6880

Dukeroyalty@newgatecomms.com

Β 

About Duke Royalty

Β 

Duke Royalty Limited provides alternative capital solutions to a diversified range of profitable and long-established businesses inΒ EuropeΒ and abroad. Duke Royalty's experienced team provide financing solutions to private companies that are in need of capital but whose owners wish to maintain equity control of their business. Duke Royalty's royalty investments are intended to provide robust, stable, long term returns to its shareholders. Duke Royalty is listed on the AIM market under the ticker DUKE and is headquartered inΒ Guernsey.

Β 

The information contained within this announcement is deemed to constitute inside information as stipulated under the Market Abuse Regulations (EU) No. 596/2014. Upon the publication of this announcement, this inside information is now considered to be in the public domain.

Β 

Β 

Β 

Β 

Β 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
Β 
END
Β 
Β 
AGRGGUCAAUPBGGC
Date   Source Headline
28th May 20267:00 amRNSNotice of Results & Investor Presentation
31st Mar 20267:00 amRNSTrading and Operational Update
19th Mar 20267:00 amRNSInterim Dividend and Dividend Declaration
26th Jan 20267:00 amRNSDirector/PDMR Shareholding
22nd Dec 20257:00 amRNSFollow-On Investment into Tristone Healthcare Ltd
22nd Dec 20257:00 amRNSFollow-On Investment into Tristone Healthcare Ltd
18th Dec 20257:00 amRNSInterim Dividend and Dividend Declaration
4th Dec 20257:00 amRNSInterim Financial Results
17th Oct 20257:00 amRNSFollow-On Investment into Step Investments Limited
1st Oct 20257:00 amRNSFollow-On Investment into Integrum Group Holdings
29th Sep 20257:00 amRNSTrading Update
18th Sep 20257:00 amRNSInterim Dividend and Dividend Declaration
4th Aug 202511:17 amRNSResult of Annual General Meeting
1st Aug 20258:08 amRNSDirector/PDMR Dealings
11th Jul 20257:00 amRNSAnnual Report & Notice of Annual General Meeting
25th Jun 20257:00 amRNSFinal Results for the year ended 31 March 2025
19th Jun 20257:00 amRNSInterim Dividend and Dividend Declaration
2nd Jun 20257:00 amRNSFollow-On Investment into Existing Capital Partner
27th May 20257:00 amRNSNotice of Results & Investor Presentation
2nd Apr 20257:00 amRNSFollow-On Investment into Existing Capital Partner
31st Mar 20257:00 amRNSTrading and Operational Update
20th Mar 20257:00 amRNSInterim Dividend and Dividend Declaration
19th Feb 20257:00 amRNSFollow-On Investment into BPVA (Ireland) Limited
30th Dec 20247:00 amRNSTrading and Operational Update
17th Dec 202412:50 pmRNSInterim Dividend and Dividend Declaration
16th Dec 20247:00 amRNSInterim Results for the six months ended 30 Sep 24
4th Dec 20249:40 amRNSDirector/PDMR Shareholding
3rd Dec 202411:34 amRNSResult of General Meeting and Issue of Equity
22nd Nov 20243:38 pmRNSResult of Retail Offer and Broker Option
15th Nov 20247:00 amRNSResult of Placing
14th Nov 20245:02 pmRNSRetail Offer to raise up to £3.0 million
14th Nov 20245:01 pmRNSIssue of Equity
30th Sep 20247:00 amRNSTrading and Operational Update
19th Sep 20247:00 amRNSInterim Dividend and Dividend Declaration
3rd Sep 20247:00 amRNSFollow-On Investment into United Glass Group
1st Aug 20243:16 pmRNSDirector/PDMR Dealings
1st Aug 202411:40 amRNSResult of Annual General Meeting
22nd Jul 20247:00 amRNSFollow-On Investment into Step Investments Limited
15th Jul 20247:00 amRNSAnnual Report & Notice of Annual General Meeting
27th Jun 20247:00 amRNSFinal Results for the year ended 31 March 2024
20th Jun 202411:50 amRNSInterim Dividend and Dividend Declaration
3rd Jun 20247:00 amRNSNotice of Results
17th May 202411:45 amEQSHardman & Co Q&A on Duke Capital (DUKE) | Generating investor returns by uniquely meeting customer needs
3rd May 20247:00 amRNSFollow-On Investment into Existing Capital Partner
29th Apr 20242:45 pmEQSHardman & Co Research Initiation of Coverage on Duke Capital (DUKE): Meeting customer needs, giving investors returns
3rd Apr 20247:00 amRNSFollow-On Investment into Existing Capital Partner
2nd Apr 20247:00 amRNSNew Capital Partner - Integrum Care
28th Mar 20247:00 amRNSTrading and Operational Update
21st Mar 20247:00 amRNSInterim Dividend and Dividend Declaration
7th Mar 20247:00 amRNSSuccessful Exit of Investment in Fabrikat

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.